NVSEF - Novartis loses patent appeal over multiple sclerosis drug

A U.S. appeals court ruled against Novartis (NYSE:NVS) (OTCPK:NVSEF) dealing a blow to Swiss drugmaker’s claims in patent lawsuit related to its blockbuster multiple sclerosis drug Gilenya. The U.S. Court of Appeals for the Federal Circuit sided with the Chinese drugmaker HEC Pharm Co rejecting Novartis’s (NVS) claims for a patent that covers a specific dosage of Gilenya, known as fingolimod in generic terms. The court reversed its earlier ruling in the case reviving HEC Pharm’s efforts to introduce a generic version for the drug. In January, the Federal Circuit upheld a decision by a Delaware court that endorsed Novartis' (NVS) patent and determined HEC's generic infringed the claims. In 2021, Gilenya added ~$2.8B of net sales Novartis (NVS) becoming its third highest sales generator for the year.

For further details see:

Novartis loses patent appeal over multiple sclerosis drug